1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Sawai’s Recent US Launches Outperform Expectations

Japanese Company Reports Modest Nine-Month Growth

 
• By Akriti Seth

Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.

Dollar - Yen
Sawai’s overall US sales remained flat while domestic sales increased • Source: Shutterstock

Sawai Pharmaceutical said recently-launched products in the US had outperformed expectations, leading the Japanese company to report growth in sales and operating income in the first nine months of its financial year ending March 2020.

Sawai had forecasted full-year turnover of ¥2.7bn ($24m) from newly-launched products. However, by the end of the third quarter, sales of ¥4.04bn had been achieved due to the contribution from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Zydus To Continue Mirabegron Sales

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list.

Sawai Reports ‘Solid Overall’ Full Year Results Despite Some Misses

 
• By Adam Zamecnik

Continuing in its medium-term business plan and company reform, Sawai forecasts its revenue to exceed ¥200bn in the coming fiscal year.

More from Business

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.